> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Arthritis Advisory Committee to Review Ofev sNDA
- URL: https://www.fdaweb.com/arthritis-advisory-committee-to-review-ofev-snda/
- Published: 2019-06-13T12:00:00.000Z
- Updated: 2026-09-15T01:32:38.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144328

*Federal Register* notice: FDA has announced a 7/25 Arthritis Advisory Committee meeting to discuss a Boehringer Ingelheim supplemental NDA for Ofev (nintedanib) capsules, indicated for treating systemic sclerosis-associated interstitial lung disease. The panel will discuss whether the application provides substantial evidence of efficacy for the proposed indication. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-12559.pdf?ref=fdaweb.com).